Repurposing antibacterial drugs identifies ridinilazole and CRS3123 as promising candidates against vancomycin-resistant enterococci.

ABSTRACT: Vancomycin-resistant enterococci (VRE) represent a growing threat to public health due to their increasing prevalence and limited treatment options. The urgent need for alternative therapeutics highlights the value of novel approaches such as drug repurposing to identify effective antimicrobial agents. In this study, we screened a library of 1,135 antibacterial compounds to identify candidates active against VRE. Fifty-eight compounds demonstrated measurable activity, with ridinilazole and CRS3123 emerging as the most promising. Both exhibited potent antibacterial activity in the nanomolar range against multiple Enterococcus species, including vancomycin-resistant and vancomycin-sensitive E. faecium, E. faecalis, E. hirae, and E. durans. CRS3123 displayed exceptional potency, with MIC valu

SUBMITTER: Abdelmegeed SM 

PROVIDER: S-EPMC12770569 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature